Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2020 / Oct / Proteomic Biomarkers: Predicting Death from Staphylococcus aureus Bacteremia
Microbiology & Immunology Microbiology and Immunology Screening and monitoring Point of care testing Technology and innovation

Proteomic Biomarkers: Predicting Death from <i>Staphylococcus aureus</i> Bacteremia

Using proteomics to predict mortality risk of Staphylococcus aureus bacteremia

By Liv Gaskill 10/09/2020 Quick Read (pre 2022) 1 min read

Share

Staphylococcus aureus bacteremia is a major cause of illness and death worldwide – and one that’s tricky to diagnose early. The longer the infection goes untreated, the more a patient’s risk of death increases. With this in mind, David Gonzalez and colleagues – proteomics specialists at the University of California San Diego School of Medicine – investigated whether proteomic and metabolomic readouts from a patient’s blood sample could serve as predictive markers of response to infection – and, ultimately, risk of mortality.

“The faster we know what’s going to happen to our patients, the better we can treat them,” said George Sakoulas, a co-author of the study (1). Over the course of two years, the team worked to identify serum proteins and metabolites in patients’ blood that could predict those most at risk of death from S. aureus bacteremia (2). By analyzing over 10,000 proteins and metabolites in more than 200 serum samples, they found that patients who died of S. aureus bacteremia exhibited a different pattern of proteins to those who survived.

The biomarkers most associated with death were lower levels of glycosylated fetuin A, unmodified fetuin B, and thyroxine, and higher levels of serum protein carbamylation. But an unanswered question remained: Do the differences actively cause increased mortality? Using a mouse model to investigate thyroxine levels, the team administered either hypo- or hyperthyroid treatment to infected mice and monitored survival rates. Compared with the control group, hyperthyroid mice had a survival rate four times higher 48 hours after infection, whereas hypothyroid mice exhibited decreased survival – suggesting that thyroxine levels directly affect disease outcome.

“This finding is a leap forward toward a point-of-care predictive tool for bacteremia risk,” said Gonzalez (1). “It also opens up lots of new basic biological questions about how our immune systems respond to infections.”

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. UC San Diego Health (2020). Available at: https://bit.ly/35WbqhU.
  2. JM Wozniak et al., Cell, 182, 1311 (2020). PMID: 32888495.

About the Author(s)

Liv Gaskill

During my undergraduate degree in psychology and Master’s in neuroimaging for clinical and cognitive neuroscience, I realized the tasks my classmates found tedious – writing essays, editing, proofreading – were the ones that gave me the greatest satisfaction. I quickly gathered that rambling on about science in the bar wasn’t exactly riveting for my non-scientist friends, so my thoughts turned to a career in science writing. At Texere, I get to craft science into stories, interact with international experts, and engage with readers who love science just as much as I do.

More Articles by Liv Gaskill

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Context Matters in Cancer Biology
Microbiology and Immunology
Context Matters in Cancer Biology

December 27, 2021

1 min read

Akoya is leading the way with spatial phenotypic signatures – a novel class of biomarkers for predicting response to immunotherapy

What’s New in Infectious Disease? (December 2021)
Microbiology and Immunology
What’s New in Infectious Disease?

December 23, 2021

1 min read

The latest research and news on COVID-19 and the infectious disease landscape

Immunology Insights
Microbiology and Immunology
Immunology Insights

January 13, 2022

1 min read

The latest research in pathology and laboratory medicine

2021: A Laboratory Medicine Roundup
Microbiology and Immunology
2021: A Laboratory Medicine Roundup

January 18, 2022

3 min read

From transgender health care to the power of pathology podcasts, we take a look at our most popular articles of the last year

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.